Publications
Stay up to date with our literature reviews which are curated by experts to feature the most important publications released each month. Explore our publications for access to concise summary slides for your own use.
January 2022
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
N Engl J Med 2019;381:841–51 DOI 10.1056/NEJMoa1901118
In the PIONEER 6 trial, the cardiovascular risk profile of oral semaglutide was noninferior to placebo over 83 weeks.